NRx Pharmaceuticals (NRXP) Competitors $1.26 +0.03 (+2.44%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NRXP vs. MNTS, CELU, CRVO, XFOR, DYAI, MURA, CNTB, ENTX, AADI, and VHAQShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Momentus (MNTS), Celularity (CELU), CervoMed (CRVO), X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), Mural Oncology (MURA), Connect Biopharma (CNTB), Entera Bio (ENTX), Aadi Bioscience (AADI), and Viveon Health Acquisition (VHAQ). NRx Pharmaceuticals vs. Momentus Celularity CervoMed X4 Pharmaceuticals Dyadic International Mural Oncology Connect Biopharma Entera Bio Aadi Bioscience Viveon Health Acquisition Momentus (NASDAQ:MNTS) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap aerospace companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Do insiders and institutionals have more ownership in MNTS or NRXP? 9.2% of Momentus shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 0.4% of Momentus shares are owned by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, MNTS or NRXP? Momentus has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Which has higher valuation & earnings, MNTS or NRXP? NRx Pharmaceuticals has lower revenue, but higher earnings than Momentus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMomentus$3.09M4.65-$68.92MN/AN/ANRx PharmaceuticalsN/AN/A-$30.15M-$2.14-0.59 Is MNTS or NRXP more profitable? NRx Pharmaceuticals has a net margin of 0.00% compared to Momentus' net margin of -1,303.93%. NRx Pharmaceuticals' return on equity of 0.00% beat Momentus' return on equity.Company Net Margins Return on Equity Return on Assets Momentus-1,303.93% -1,945.42% -217.16% NRx Pharmaceuticals N/A N/A -449.16% Does the MarketBeat Community prefer MNTS or NRXP? NRx Pharmaceuticals received 9 more outperform votes than Momentus when rated by MarketBeat users. Likewise, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 25.00% of users gave Momentus an outperform vote. CompanyUnderperformOutperformMomentusOutperform Votes225.00% Underperform Votes675.00% NRx PharmaceuticalsOutperform Votes11100.00% Underperform VotesNo Votes Does the media prefer MNTS or NRXP? In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Momentus. MarketBeat recorded 9 mentions for NRx Pharmaceuticals and 0 mentions for Momentus. Momentus' average media sentiment score of 0.38 beat NRx Pharmaceuticals' score of 0.32 indicating that Momentus is being referred to more favorably in the media. Company Overall Sentiment Momentus Neutral NRx Pharmaceuticals Neutral Do analysts recommend MNTS or NRXP? NRx Pharmaceuticals has a consensus price target of $31.50, suggesting a potential upside of 2,400.00%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Momentus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Momentus 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryNRx Pharmaceuticals beats Momentus on 12 of the 16 factors compared between the two stocks. Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.23M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-0.5911.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book-0.8110.377.096.50Net Income-$30.15M$153.60M$119.65M$226.22M7 Day Performance5.88%4.60%2.25%4.03%1 Month Performance4.13%-6.29%-2.33%4.92%1 Year Performance-95.78%33.41%33.98%29.30% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals2.0179 of 5 stars$1.26+2.4%$31.50+2,400.0%-95.8%$15.23MN/A-0.592MNTSMomentusN/A$0.56-3.4%N/A-81.5%$14.38M$3.09M0.00120News CoverageCELUCelularity0.536 of 5 stars$2.76-3.2%N/A+34.0%$60.69M$22.77M0.00220News CoverageCRVOCervoMed1.323 of 5 stars$9.60+0.2%$53.60+458.3%-3.7%$59.23M$7.14M0.004High Trading VolumeXFORX4 Pharmaceuticals4.2896 of 5 stars$0.34-8.2%$2.88+750.6%-55.6%$57.65M$1.12M-3.7680Analyst RevisionDYAIDyadic International2.1119 of 5 stars$1.93+15.6%$6.00+210.9%+6.0%$57.11M$3.36M-8.657News CoverageHigh Trading VolumeMURAMural Oncology3.2942 of 5 stars$3.35-0.6%$16.00+377.6%N/A$57.02MN/A-0.36119Positive NewsCNTBConnect Biopharma3.0402 of 5 stars$1.03+4.0%$8.00+676.7%-16.9%$56.91MN/A0.00110ENTXEntera Bio1.8457 of 5 stars$1.59-1.9%$10.00+528.9%+120.8%$56.90M$99,000.00-6.3520AADIAadi Bioscience1.1825 of 5 stars$2.30+0.9%$1.67-27.5%-51.6%$56.70M$24.35M-1.0040VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$56.60MN/A0.002News CoverageHigh Trading Volume Related Companies and Tools Related Companies Momentus Alternatives Celularity Alternatives CervoMed Alternatives X4 Pharmaceuticals Alternatives Dyadic International Alternatives Mural Oncology Alternatives Connect Biopharma Alternatives Entera Bio Alternatives Aadi Bioscience Alternatives Viveon Health Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRXP) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
